Related Experiment Video

Updated: Feb 24, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

776

Comparisons of cancer staging systems should be based on overall performance in the population

Kathleen F Kerr1, Michael LeBlanc2, Holly Janes2

  • 11 Department of Biostatistics, University of Washington, Seattle, WA, USA.

Clinical Trials (London, England)
|August 19, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

953
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Related Experiment Videos

Last Updated: Feb 24, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

776
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

953
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

796
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
796
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

658
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
658

Articles linked to this work by shared authors, journal, and citation graph.

Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma.

JCO oncology advances·2026

Donor Urinary Biomarkers and the Prediction of Deceased Donor Allograft Function.

Journal of the American Society of Nephrology : JASN·2026

Leadership and Managerial Development Needs of Pharmacy Leaders in Canadian Health Care Systems: Results from a National Questionnaire.

The Canadian journal of hospital pharmacy·2026

Perspectives on Leadership Development and Learning Needs of Pharmacy Leaders in Canadian Health Care Systems: A Qualitative Study.

The Canadian journal of hospital pharmacy·2026

Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs.

The oncologist·2026

A General Framework for Designing and Evaluating Active-Controlled Trials with Non-Inferiority Objectives.

Statistics in medicine·2026

How to be SMART in oncology: A practical framework to assess the contribution of phase using sequential multiple adaptive randomized treatment designs.

Clinical trials (London, England)·2026

A practical application for the efficient use of historical data in randomized controlled design using systematic review data.

Clinical trials (London, England)·2026

Effectiveness of the recruitment strategies used in the Baby-Feed Online Trial, a trial to test an educational web application for caregivers to prevent excessive weight gain in infants.

Clinical trials (London, England)·2026

Adaptive versus fixed designs in confirmatory clinical trials: centering the choice on ethics.

Clinical trials (London, England)·2026

Design and monitoring of randomized trials in vision research with binary endpoints.

Clinical trials (London, England)·2026

A statistical evaluation of decision-making methods and the efficiency of Bayesian multi-arm multi-stage trials.

Clinical trials (London, England)·2026

Epstein-Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review.

The Lancet regional health. Western Pacific·2026

Clinical and prognostic value of dynapenia in patients with head and neck cancer: a multicenter cohort study. VALOR group.

Frontiers in nutrition·2026

Intravascular Imaging to Predict the Coronary No-Reflow and Slow-Flow Phenomena: Advances and Perspectives.

Reviews in cardiovascular medicine·2026

Advances in galactose-based small-molecule hepatocyte-targeting probes for detecting biomarkers in hepatocellular carcinoma.

Frontiers in chemistry·2026

Risk factors and development of a nomogram prediction model for urinary dysfunction after laparoscopic radical surgery for rectal cancer.

Frontiers in surgery·2026

The Acidic Exosomal miR-1246/WASF3 Axis Regulates Hepatic Stellate Cell Activation and Stiff ECM Remodeling to Promote Pancreatic Ductal Adenocarcinoma Liver Metastasis.

International journal of biological sciences·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us